D
Daniel Ford
Researcher at Birmingham City Hospital
Publications - 7
Citations - 225
Daniel Ford is an academic researcher from Birmingham City Hospital. The author has contributed to research in topics: Cabazitaxel & Docetaxel. The author has an hindex of 4, co-authored 7 publications receiving 178 citations.
Papers
More filters
Journal ArticleDOI
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Mario A. Eisenberger,Anne-Claire Hardy-Bessard,Choung Soo Kim,Lajos Géczi,Daniel Ford,Loic Mourey,Joan Carles,Phillip Parente,Albert Font,Gabriel Kacso,Mustapha Chadjaa,Wenping Zhang,John Bernard,Johann S. de Bono +13 more
TL;DR: The efficacy of cabazitaxel in postdocetaxel patients with mCRPC was confirmed and the noninferiority end point was met; C20 maintained ≥ 50% of the OS benefit of C25 versus mitoxantrone in TROPIC.
Journal ArticleDOI
The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers.
Robert L. Stevenson,David Gareth Fackrell,Daniel Ford,John Glaholm,Ahmed El-Modir,Emilio Porfiri,Anjali Zarkar,Jacob Tanguay,Thomas Rackley,Nicholas D. James +9 more
TL;DR: Ez has recently become available, via the UK cancer drugs fund (CDF), for progressive disease post docetaxel, prior to exposure to Abi, and patients who started treatment between the August 2012 and April 2013 were identified.
Journal ArticleDOI
PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
J.S. de Bono,A-C. Hardy-Bessard,Choung Soo Kim,Lajos Géczi,Daniel Ford,Loic Mourey,Joan Carles,Phillip Parente,Albert Font,Gabriel Kacso,Mustapha Chadjaa,Wenping Zhang,John Bernard,Mario A. Eisenberger +13 more
Journal ArticleDOI
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen
Mario A. Eisenberger,Anne-Claire Hardy-Bessard,Loic Mourey,Paul N. Mainwaring,Daniel Ford,Jeremy Shapiro,Joan Carles,Siobhan Ng,Thierry Gil,Boris Alekseev,Sergey Ivanov,Thomas Facchini,Eric Legouffe,Oleg I. Apolikhin,Hardev Pandha,Aart Beeker,Oleg Karyakin,Wendy Zhang,Mustapha Chadjaa,Johann S. de Bono +19 more
TL;DR: It is of interest to assess if reducing the Cbz approved dose in mCRPC lessens hematologic toxicity and is non-inferior to recommended doses.
Journal ArticleDOI
PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Mario A. Eisenberger,Anne-Claire Hardy-Bessard,Daniel Ford,Loic Mourey,Phillip Parente,Paul N. Mainwaring,Siobhan Ng,Boris Alekseev,Vsevolod Matveev,Joan Carles,Jeremy Shapiro,Igor Latorzeff,Istvan Bodrogi,Choung-Soo Kim,Albert Font,Roanne J. Segal,Hendrik van den Berg,Wenping Zhang,Mustapha Chadjaa,Johann S. de Bono +19 more
TL;DR: An established safety profile and significantly improves overall survival (OS) vs mitoxantrone + P in pts with mCRPC previously treated with a D-containing regimen are shown.